Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 2/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.32 |
| ▸ | HTR3B | O95264 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR3A | P46098 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17254458 | 0.76 | KDM4E (0.58) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL29895259 | 0.75 | CYP11B2 (0.41) | GABRA5ALDH1A1KDM4ELCKTBXAS1 | |
| SCHEMBL970053 | 0.74 | KDM4E (0.59) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL29742732 | 0.74 | KDM4E (0.59) | ALDH1A1KDM4EGLAGAAHPGD | |
| SCHEMBL3320683 | 0.74 | HRH4 (0.36) | GABRA5ALDH1A1KDM4ELCKHRH4 | |
| SCHEMBL10681757 | 0.71 | GABRA5 (0.36) | GABRA5ALDH1A1KDM4EGLAGAA | |
| SCHEMBL15471902 | 0.70 | HRH4 (0.45) | ALDH1A1KDM4EHSD17B10HRH4MEN1 | |
| SCHEMBL31060458 | 0.70 | LCK (0.40) | GABRA5LCKHRH4HTR3EHTR3B | |
| SCHEMBL4038518 | 0.70 | LCK (0.41) | GABRA5LCKHRH4HTR3EHTR3B | |
| SCHEMBL31307208 | 0.69 | KDM4E (0.37) | GABRA5ALDH1A1KDM4EGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875618-B2 | 8-chloro-3,4-dimethyl-1-(2- methylphenyl)imidazo[1,5- a]quinoxaline; inhibitors of phosphodiesterase 10; for treatment of central nervous system disorders (cognitive deficits, social phobia, reduced vigilance, obesity and psychosis) | WYETH (US) | 2011-01-25 | — | — | US | disclosed |
| EP-2227472-A1 | ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Elbion Gmbh (DE) | 2010-09-15 | — | — | EP | disclosed |
| EP-2225248-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | Wyeth LLC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090239874-A1 | Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them | HOFGEN NORBERT | 2009-09-24 | — | — | US | disclosed |
| US-7550465-B2 | Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them | ELBION GMBH (DE) | 2009-06-23 | — | — | US | disclosed |
| WO-2009070583-A1 | PYRIDO[3,2-E]PYRAZINES, PROCESS FOR PREPARING THE SAME, AND THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068246-A2 | METHODS OF TREATING OBESITY AND METABOLIC DISORDERS | ELBION GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009068246-A2 | METHODS OF TREATING OBESITY AND METABOLIC DISORDERS | ELBION GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009070584-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-A]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143392-A1 | Methods of Treating Obesity and Metabolic Disorders | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068320-A1 | ARYL AND HETEROARYL FUSED IMIDAZO (1,5-A) PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20090143391-A1 | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 | ELBION GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| EP-2021342-A1 | PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | Elbion Gmbh (DE) | 2009-02-11 | — | — | EP | disclosed |
| EP-2021341-A1 | 4-AMINO-PYRIDOÝ3,2-e¨PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | Elbion Gmbh (DE) | 2009-02-11 | — | — | EP | disclosed |
| US-20080027064-A1 | Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them | ELBION GMBH (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20070299079-A1 | 4-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | ELBION AG (DE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007137820-A1 | PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | ELBION GMBH (DE) | 2007-12-06 | — | — | WO | disclosed |
| WO-2007137819-A1 | 4-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | ELBION GMBH (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143361-A1 | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 | PDE12, PDE5A, PDE3A | GABRA5 2231/4885ALDH1A1 1079/4885KDM4E 790/4885 |
| US-20080027064-A1 | Pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them | PDE12, PDE7A, PDE5A | GABRA5 1135/4885ALDH1A1 1084/4885KDM4E 1036/4885 |
| US-20090143391-A1 | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphodiesterase 10 | PDE12, PDE5A, PDE10A | GABRA5 550/4885ALDH1A1 409/4885KDM4E 1377/4885 |
| US-20090239874-A1 | Pyrido[3,2-e]pyrazines, their use as inhibitors of phospohodiesterase 10, and processes for preparing them | PDE7A, PDE12, PNPO | GABRA5 1312/4885ALDH1A1 1239/4885KDM4E 1334/4885 |
| US-20090143367-A1 | ARYL AND HETEROARYL FUSED IMIDAZO[1,5-a]PYRAZINES AS INHIBITORS OF PHOSPHODIESTERASE 10 | PDE12, PDE5A, PDE10A | GABRA5 550/4885ALDH1A1 409/4885KDM4E 1377/4885 |
| US-20090143392-A1 | Methods of Treating Obesity and Metabolic Disorders | PDE12, PDE2A, PDE5A | GABRA5 2095/4885ALDH1A1 677/4885KDM4E 1088/4885 |
| US-20070299079-A1 | 4-AMINO-PYRIDO[3,2-e]PYRAZINES, THEIR USE AS INHIBITORS OF PHOSPHODIESTERASE 10, AND PROCESSES FOR PREPARING THEM | PDE12, PDE5A, PDE7A | GABRA5 1058/4885ALDH1A1 855/4885KDM4E 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.